Mitrade Insights is dedicated to providing investors with rich, timely and most valuable financial information to help investors grasp the market situation and find timely trading opportunities.

2021

Best News & Analysis Provider

FxDailyInfo

2022

Best Forex Educational Resources Global

International Business Magazine

Insights

News

Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?

Source The Motley Fool

Key Points

Regeneron's stock has underperformed the market this year, but it got a boost last time it reported earnings.
The company's revenue grew by 17% last quarter, and multiple drugs hit all-time highs.
The stock trades at a low earnings multiple when compared to the S&P 500 average.
10 stocks we like better than Regeneron Pharmaceuticals ›

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is having an underwhelming year, down around 1% thus far. It's been a quality growth stock to own for the long haul, and with some terrific assets in its portfolio, it has the potential to perform much better in the long run.

Next month, on Oct. 30, it will release its third-quarter earnings results. A solid round of results could be just what's needed for the healthcare stock to rally. Is it a good buy before then?

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

Four scientists in lab coats review research notes together in a bright laboratory.

Image source: Getty Images.

The company's most recent results gave the stock a boost

When Regeneron last reported earnings in late July, the numbers were strong, and gave the stock a boost in the days and weeks afterward. The company's revenue for the quarter, which went up until the end of June, totaled $4.3 billion and rose 17% year over year. Global sales of Dupixent and Libtayo were particularly strong, rising by 38% and 30%, respectively. Revenue for Eylea HD in the U.S. was also up an impressive 52%.

As a result of the strong numbers, the stock would end up rising afterward, eventually hitting a new 52-week high in early September. It's come down from those highs since, but if there's another strong quarter of growth, Regeneron's stock may rally once again, especially if its growth rate, which hasn't been all that strong in recent years, remains in double-digits yet again.

REGN Revenue (Quarterly YoY Growth) Chart

REGN Revenue (Quarterly YoY Growth) data by YCharts

Regeneron may be a slam-dunk buy right now

Although it hasn't been a great year for Regeneron, this is a healthcare stock that could have plenty of room to rise much higher given its solid results, modest valuation, and tremendous growth prospects.

Not only is the business growing at a decent pace of late, but it also has a strong pipeline of drugs, with around 50 product candidates in development, which could pave the way for much more growth in the future.

Meanwhile, with the stock trading at only 19 times trailing earnings and falling to a multiple of less than 15 based on future profits (based on analyst expectations), it makes for a solid value buy. By comparison, the average stock on the S&P 500 trades at more than 23 times its trailing profits and roughly 20 times forward earnings.

Regeneron's stock may be overdue for a bigger rally. Its last earnings report gave the stock a bit of a boost, and the same might happen again after it releases its latest numbers in late October. But whether that happens or not, for long-term investors, now can be a terrific time to load up on this top growth stock.

Should you buy stock in Regeneron Pharmaceuticals right now?

Before you buy stock in Regeneron Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Regeneron Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $383,680!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,382,954!*

Now, it’s worth noting Stock Advisor’s total average return is 937% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of September 28, 2026.

David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Recommended Articles

【Daily Brief】10-year Treasury yield briefly tops 5%, S&P 500 slips to 7,602 and the dollar firms at 99.3 as the Fed's decision eve begins The 10-year Treasury yield touched 5.014% on Monday — its first print above 5% since October 2023 — while the S&P 500 closed 0.48% lower at 7,619.98 and the dollar index firmed to 99.3. Here is the full market wrap ahead of Wednesday's FOMC decision, the dot plot and the August retail sales report, plus today's CLARITY Act Senate vote.

Author Irene Q.

Sep 15, Tue

The 10-year Treasury yield touched 5.014% on Monday — its first print above 5% since October 2023 — while the S&P 500 closed 0.48% lower at 7,619.98 and the dollar index firmed to 99.3. Here is the full market wrap ahead of Wednesday's FOMC decision, the dot plot and the August retail sales report, plus today's CLARITY Act Senate vote.

October hike odds climb toward 60% as Goldman and BofA both flip — what Warsh's "dose of accommodation" really changed Rate futures now price roughly 55% to 62% for a 25bp hike at the October 27-28 FOMC, up from about 30% before Chair Warsh's post-meeting framing that the Fed is merely "removing some accommodation." Goldman Sachs has added an October hike to its forecast and Bank of America now sees moves in both October and December. Here is the repricing, the language behind it, and the two data points that decide it.

Author Irene Q.

Sep 23, Wed

Rate futures now price roughly 55% to 62% for a 25bp hike at the October 27-28 FOMC, up from about 30% before Chair Warsh's post-meeting framing that the Fed is merely "removing some accommodation." Goldman Sachs has added an October hike to its forecast and Bank of America now sees moves in both October and December. Here is the repricing, the language behind it, and the two data points that decide it.

Four jobs reports in five days: what JOLTS, ADP, claims and the September payrolls mean for the October Fed decision The US labour market faces its densest data week of the month. JOLTS job openings land Tuesday (7.2 million expected), ADP on Wednesday (70,000 expected), initial claims on Thursday and the September non-farm payrolls on Friday (100,000 expected, down from 162,000). Markets price a 64%-70% chance of another quarter-point Fed hike on October 28. The dollar index sits at 100.77 and the S&P 500 at 7,729.8.

Author Mitrade

Sep 28, Mon

The US labour market faces its densest data week of the month. JOLTS job openings land Tuesday (7.2 million expected), ADP on Wednesday (70,000 expected), initial claims on Thursday and the September non-farm payrolls on Friday (100,000 expected, down from 162,000). Markets price a 64%-70% chance of another quarter-point Fed hike on October 28. The dollar index sits at 100.77 and the S&P 500 at 7,729.8.

Nvidia's $150 billion buyback landed — and the AI sector fell anyway. That's the signal worth trading Nvidia closed up 1.68% at $228.86 on 28 September after announcing a $150 billion share repurchase authorisation, the largest single corporate buyback on record, while the rest of the AI complex sold off: AMD -3.6%, Micron -2.6%, Meta -4.8% and the Philadelphia Semiconductor Index -1.61%. The divergence is not noise. Capital is rotating toward cash-flow certainty, not abandoning the AI theme. With Micron reporting after the close on 30 September, here is what the split means.

Author Irene Q.

20 hours ago

Nvidia closed up 1.68% at $228.86 on 28 September after announcing a $150 billion share repurchase authorisation, the largest single corporate buyback on record, while the rest of the AI complex sold off: AMD -3.6%, Micron -2.6%, Meta -4.8% and the Philadelphia Semiconductor Index -1.61%. The divergence is not noise. Capital is rotating toward cash-flow certainty, not abandoning the AI theme. With Micron reporting after the close on 30 September, here is what the split means.

The 30-year Treasury just hit a 22-year high — and the bond market is not pricing the Fed, it is pricing the deficit The 30-year Treasury yield closed at 5.56% on 28 September, the highest since June 2004, while the 10-year reached 5.24% and the 20-year 5.60%. The curve has steepened roughly 30bp in eight sessions even as October hike odds sit at 70.3%. That gap is the story: the long end is repricing fiscal and inflation risk, not policy. With PCE on Wednesday and payrolls on Friday, here is what the long end is really saying.

Author Irene Q.

19 hours ago

The 30-year Treasury yield closed at 5.56% on 28 September, the highest since June 2004, while the 10-year reached 5.24% and the 20-year 5.60%. The curve has steepened roughly 30bp in eight sessions even as October hike odds sit at 70.3%. That gap is the story: the long end is repricing fiscal and inflation risk, not policy. With PCE on Wednesday and payrolls on Friday, here is what the long end is really saying.

Popular Symbols